Gene · 5499
Papers4,146
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 4,146
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effect of coronaviruses on blood vessel permeability: potential therapeutic targets. | Ther Adv Respir Dis | 2023 | 37067023 | PubTator, text mining | PubMed |
| Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. | EBioMedicine | 2023 | 37060743 | PubTator, text mining | PubMed |
| Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment. | Nat Commun | 2023 | 37059708 | PubTator, text mining | PubMed |
| Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. | J Pharmacol Sci | 2023 | 37059487 | PubTator, text mining | PubMed |
| AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro. | J Chem Inf Model | 2023 | 37058135 | PubTator, text mining | PubMed |
| SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction. | J Biol Chem | 2023 | 37044215 | PubTator, text mining | PubMed |
| Dephosphorylation of neural wiring protein shootin1 by PP1 phosphatase regulates netrin-1-induced axon guidance. | J Biol Chem | 2023 | 37044214 | PubTator, text mining | PubMed |
| Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination. | Eur J Med Chem | 2023 | 37043904 | PubTator, text mining | PubMed |
| COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. | MedComm (2020) | 2023 | 37041762 | PubTator, text mining | PubMed |
| Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. | Technol Health Care | 2023 | 37038790 | PubTator, text mining | PubMed |
| Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease. | Protein Expr Purif | 2023 | 37030644 | PubTator, text mining | PubMed |
| COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. | Drug Discov Today | 2023 | 37028502 | PubTator, text mining | PubMed |
| Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy. | Eur Heart J Cardiovasc Pharmacother | 2023 | 37019821 | PubTator, text mining | PubMed |
| Zooanthroponotic transmission of SARS-CoV-2 and host-specific viral mutations revealed by genome-wide phylogenetic analysis. | Elife | 2023 | 37014792 | PubTator, text mining | PubMed |
| Evasion strategies of porcine reproductive and respiratory syndrome virus. | Front Microbiol | 2023 | 37007469 | PubTator, text mining | PubMed |
| The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. | Antiviral Res | 2023 | 37003304 | PubTator, text mining | PubMed |
| Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction. | Nat Commun | 2023 | 37002212 | PubTator, text mining | PubMed |
| Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2. | Antiviral Res | 2023 | 36997073 | PubTator, text mining | PubMed |
| Shared peripheral blood biomarkers for Alzheimer's disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis. | Heliyon | 2023 | 36994393 | PubTator, text mining | PubMed |
| Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2. | Viruses | 2023 | 36992394 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5499/papers?page=17